Syngenta signs global commercial agreement with Novozymes - Addition of a key biofungicide to complement Syngenta's offer - Novel control of damaging diseases across various crops - Exclusive global marketing and distribution agreement PR Newswire BASEL, Switzerland, Oct. 26, 2012 BASEL, Switzerland, Oct. 26, 2012 /PRNewswire/ -- Syngenta and Novozymes today announced an exclusive global marketing and distribution agreement to commercialize Taegro^®, a fermented biological fungicide based on a naturally occurring bacterium Bacillus subtilis. It offers growers broad-spectrum disease control at very low application rates in a variety of crops. Its multiple modes of action make it highly complementary to Syngenta's extensive fungicide portfolio. In April, Syngenta and Novozymes announced a global agreement to commercialize the Novozymes technology JumpStart^®, a seed-applied biological that increases phosphate solubility in the soil. John Atkin, Chief Operating Officer, said: "We are delighted to enter into another agreement to commercialize a Novozymes technology. Having worldwide commercial rights for Taegro will further strengthen our ability to offer high-performing integrated crop solutions." Thomas Videbaek, Executive Vice President Novozymes, commented: "This collaboration matches Syngenta's global market strength and leading position within fungicides and integrated solutions with Novozymes' deep know-how on sustainable, bio-based technologies." Expanding the existing registrations of Taegro in the U.S., the companies aim to offer the technology to growers around the world for use on a broad range of crops. Financial details about the agreement were not disclosed. Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com. CautionaryStatement Regarding Forward-Looking Statements This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor. SyngentaInternationalAG Analyst/Investor contact: Media Office Media contact: CH-4002Basel Jennifer Gough Switzerland Paul Barrett Switzerland +41 61 323 Tel: +41 61 323 Switzerland +41 61 5059 2323 323 2323 USA +1 202 Fax: +41 61 323 737 6521 2424 www.syngenta.com SOURCE Syngenta Website: http://www.syngenta.com
Syngenta signs global commercial agreement with Novozymes
Press spacebar to pause and continue. Press esc to stop.